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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Obesity and related adipocytokine disbalance increase the risk of
hepatocellular carcinoma. To determine the impact of increased
levels of leptin, an obesity related adipocytokine, on the recurrence
of hepatocellular carcinoma, we conducted a prospective case series
analysis. Eighty five consecutive primary hepatocellular carcinoma
patients at our hospital from January 2006 to December 2008
were analyzed. Serum leptin level significantly correlated with
Body Mass Index, total body fat, and the amount of subcutaneous
fat. They included 33 with stage I/II, who underwent curative
treatment. The factors contributing to recurrence of hepato 
cellular carcinoma, including leptin, were subjected to univariate
and multivariate analyses using the Cox proportional hazards
model. Body Mass Index (p = 0.0062), total body fat (p = 0.0404),
albumin (p = 0.0210),  α fetoprotein (p = 0.0365), and leptin
(p = 0.0003) were significantly associated with the recurrence of
hepatocellular carcinoma in univariate analysis. Multivariate
analysis suggested that leptin (hazard ratio 1.25, 95% CI 1.07–1.49,
p = 0.0035) was a sole independent predictor. Kaplan Meier analysis
showed that recurrence free survival was lower in patients with
greater serum leptin concentrations (>5 ng/mL, p = 0.0221). These
results suggest that the serum leptin level is a useful biomarker
for predicting the early recurrence of hepatocellular carcinoma.
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Introduction Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide and is estimated to cause approxi-
mately 500,000 deaths annually.(1) HCC frequently develops and
in many cases recurs in cirrhotic livers due to persistent hepatitis
B virus (HBV) and hepatitis C virus (HCV) infection; this is
strongly associated with poor prognosis for this particular
malignancy.(2) Therefore, careful surveillance of high-risk groups
for HCC is important to improve prognosis. Hence, there is a
critical need to identify useful risk factors for the development
of HCC. Infection with HBV and HCV, alcohol consumption,
aflatoxin exposure, and immune-related hepatitis are accepted as
significant risk factors for the development of primary HCC.(3)
Male gender, the presence of cirrhosis, high α-fetoprotein (AFP),
large tumor foci, multiplicity of tumors, pathologically high-grade
atypia of tumor cells, and the presence of portal venous invasion of
tumors also raise the risk for HCC recurrence.(4–8)
In addition to these factors, recent studies demonstrate that
obesity(9) and related metabolic abnormalities—especially diabetes
mellitus (DM) and insulin resistance(10,11)—are important risk
factors for the development of HCC. For instance, insulin resis-
tance significantly raises the risk of the recurrence of stage I HCC
after curative treatment.(10) Several pathophysiological mecha-
nisms linking obesity and HCC development have been proposed
and include the emergence of insulin resistance and a state of
chronic inflammation.(12,13) Adipocytokine disbalance might also
be involved in obesity-related liver carcinogenesis.(14) Among the
adipocytokines, it is well known that the serum levels of leptin,
which regulate the homeostasis of glucose and lipid metabo-
lism,(15) are elevated in obese individuals.(16) In addition, both in
vitro and in vivo studies indicate that leptin might play a role in the
development of several types of human malignancies, including
HCC.(17–21) These findings suggest that the dysregulation of serum
leptin levels may be a critical link between obesity and liver
carcinogenesis. However, whether leptin is a significant bio-
marker for predicting the development and/or recurrence of HCC
has not been explored.
In this study, we measured the serum leptin concentration in
patients with HCC and examined whether it is correlated with
obesity and insulin resistance. In addition, we designed a prospec-
tive case-series analysis to examine the recurrence-free survival in
consecutive patients with stage I/II HCC, who received curative
treatment by surgical resection or radiofrequency ablation (RFA),
stratified by serum leptin concentrations.
Materials and Methods
Patients. From January 2006 to December 2008, 85 primary
HCC patients underwent initial treatment at our hospital. We
measured visceral and subcutaneous fat volume using computed
tomography (CT) scans at the umbilical level according to a
previously reported technique (fatAnalyses and EV Insite R, PSP
Corporation, Tokyo, Japan).(22) Tumor stage was defined according
to the staging system of the Liver Cancer Study Group of Japan
(LCSGJ).(23) HCC nodules were detected by imaging modalities
including abdominal ultrasonography (US), dynamic CT, dynamic
magnetic resonance imaging (MRI), and abdominal arteriography.
The diagnosis of HCC was made from a typical hypervascular
tumor stain on angiography and a typical dynamic-study finding
of enhanced staining in the early phase and attenuation in the
delayed phase.
Treatment, follow up, and determination of recurrence.
Fifteen patients were treated with surgical resection, 41 with RFA,
19 with transarterial chemoembolization (TACE), and 10 with
transarterial infusion (TAI). Among them, we selected 33 curative
cases that met the following criteria: tumor stage classified as I or
II; and surgical resection or RFA conducted for the initial HCC
treatment. In all 33 cases, therapeutic effects were judged to be
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curative using dynamic CT or MRI exhibiting a complete dis-
appearance of the imaging characteristics of HCC described above.
Patients were thereafter followed up on a monthly outpatient
basis using serum tumor markers every month, such as AFP and
proteins induced by vitamin K absence or antagonists-II (PIVKA-
II), and by abdominal US, dynamic CT scanning, or dynamic MRI
every 3 months. Recurrent HCC was diagnosed, using the imaging
modalities described earlier, by the appearance of other lesions
differed from the primary lesions. The follow-up period was
defined as the interval from the date of initial treatment until the
date of diagnosis of recurrence or until April 2009 if HCC did not
recur.
Statistical analysis. The Pearson product-moment correla-
tion coefficient was used for measuring the linear correlation
between 2 continuous variables. Recurrence-free survival was
estimated using the Kaplan-Meier method, and differences between
curves were examined with a log-rank test. Baseline characteristics
were compared using Student’s t test for continuous variables
or the χ2 test for categorical variables. There were 17 possible
predictors for the recurrence of HCC after the initial curative
treatment: sex, age, body mass index (BMI), total body fat,
amounts of both visceral and subcutaneous fat, the presence of
HCV-antibodies (HCV-Ab), Child-Pugh classification, serum
albumin concentration, platelet count, homeostasis model assess-
ment of insulin resistance (HOMA-IR = fasting plasma glucose
(mg/dL) × fasting immunoreactive insulin (μU/mL)/405), hemo-
globin A1c (HbA1c), serum tumor markers (AFP and PIVKA-II),
initial treatment for HCC, tumor stage, and serum leptin concen-
tration. Parameters that were significant as determined by
univariate analysis were then subjected to multivariate analyses
using the Cox proportional hazards model. Statistical significance
was defined as p<0.05.
Results
Baseline characteristics and laboratory data of patients.
The baseline characteristics and laboratory data of 85 patients
(54 men and 31 women, median age 73 years) are shown in
Table 1. The median follow-up period was 484 days (range, 14–
1,429 days). Median BMI was 23.2 kg/m2, which was classified in
the normal range according to the WHO classification of obesity
(http://www.who.int/bmi). Median free plasma glucose (FPG),
free immunoreactive insulin (FIRI), HOMA-IR, and HbA1c were
97 mg/dL, 8.115 µU/mL, 2.245, and 5.3%, respectively. The
median serum leptin concentration was 5.0 ng/mL (range 1.4–26.6).
Association of the serum leptin concentration with obesity
and insulin resistance. Four obesity-related factors were tested
for possible association with the serum leptin concentration:
BMI, total body fat, and the amounts of visceral and subcutaneous
fat (Fig. 1). For BMI analysis, we excluded 7 patients with CT-
detected ascites. The Pearson product-moment correlation coeffi-
cient and p values of BMI and the total body fat with serum leptin
concentration were r = 0.4559 and p<0.0001, and r = 0.3560
and p = 0.0008, respectively; indicating that these 2 factors were
significantly correlated with the serum leptin concentration. The
amount of subcutaneous fat (r = 0.5174 and p<0.0001) was also
strongly correlated with the serum leptin level, whereas the
amount of visceral fat (r = 0.0987 and p = 0.3776) was not. In
addition, no significant correlations were noted between the
serum leptin concentration and insulin resistance-related factors,
including FPG (r = −0.0816 and p = 0.4579), FIRI (r = 0.1049 and
p = 0.3378), HOMA-IR (r = 0.0506 and p = 0.6385), and HbA1c
(r = 0.0194 and p = 0.7820).
Possible risk factors for the recurrence of HCC. In all 33
curative cases of stage I/II HCC, 12 patients experienced recur-
Table 1. Baseline demographic and clinical characteristics
Values are median [range]. *B means positive for hepatitis B surface antigen and C means positive
for hepatitis C virus antibody. AFP, α fetoprotein; B, hepatitis B virus; BMI, body mass index;
C, hepatitis C virus; FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HbA1c,
hemoglobin A1c; HCC, hepatocellular carcinoma; HOMA IR, homeostasis model assessment of
insulin resistance; PIVKA II, protein induced by vitamin K absence or antagonists II; RFA, radio 
frequency ablation; TACE, transarterial chemoembolization; TAI, transarterial infusion.
Variable Total patients (n =8 5 )
Sex (male/female) 54/31
Age (years) 73 [36–87]
BMI (kg/m2) 23.2 [17.5–30.7]
Total body fat (cm2) 188.81 [12.93–501.8]
Amount of visceral fat (cm2) 76.43 [3.82–359.83]
Amount of subcutaneous fat (cm2) 105.66 [9.11–265.26]
Etiology (B/C/B + C/other)* 8/55/2/20
Child Pugh classification (A/B/C) 60/23/2
Ascites on CT imaging (present/absent) 7/78
ALB (g/dL) 3.5 [2.2–4.5]
PLT (×104/μL) 11.7 [3.0–76.4]
FPG (mg/dL) 97 [67–271]
FIRI (μU/mL) 8.115 [1.21–90.2]
HOMA IR 2.245 [0.27–28.28]
HbA1c (%) 5.3 [3.7–10.3]
Leptin (ng/mL) 5.0 [1.4–26.6]
Stage (I/II/III/IVA/IVB) 19/26/27/10/3
Initial treatment for HCC (resection/RFA/TACE/TAI) 15/41/19/10
AFP (ng/mL) 48 [0–222000]
PIVKA II (mAU/mL) 170 [7–474000]
Follow up period (days) 484 [14–1429] J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 155
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rence in the liver, but none exhibited distant metastasis. The 1-year
recurrence-free survival in the 33 patients was 79% (Fig. 2a).
Fig. 2b shows Kaplan-Meier curves for recurrence-free survival
divided into 2 subgroups on the basis of median serum leptin
concentration (≤5 or >5 ng/mL), which results in a significant
difference (p = 0.0221).
The Cox proportional hazards model was used to analyze risk
factors for the recurrence of stage I/II HCC after curative
treatments using the 17 variables listed in Table 2. BMI (hazard
ratio 1.30, 95% CI 1.08–1.56, p = 0.0062), total body fat (hazard
ratio 1.00, 95% CI 1.00–1.01, p = 0.0404), serum albumin
concentration (hazard ratio 0.26, 95% CI 0.08–0.81, p = 0.0210),
AFP (hazard ratio 0.99, 95% CI 0.99–0.99, p = 0.0365), and serum
leptin concentration (hazard ratio 1.29, 95% CI 1.12–1.50,
p = 0.0003) were identified as significant risk factors by univariate
analysis. Multivariate analysis only identified serum leptin
concentration (hazard ratio 1.25, 95% CI 1.07–1.49, p = 0.0035)
as significant independent risk factor for the recurrence of HCC
(Table 3).
Table 4 shows the baseline characteristics and laboratory data
of patients divided on the basis of the serum leptin concentration
(≤5 and >5 ng/mL). No significant differences were noted
between the 2 subgroups, except the amount of subcutaneous
fat (p = 0.0461).
Discussion
Leptin regulates body weight by signaling information to the
brain regarding the availability of energy stored as fat; this
negative feedback loop is disrupted in most obese individuals and
results in a state known as leptin resistance.(16,24) Consistent with
the results of previous studies,(16,24) the serum leptin concentration
was significantly correlated with BMI and total body fat in the
present study (Fig. 1 a and b). These parameters were also
significant risk factors for the recurrence of HCC as determined
by univariate analysis (Table 2); however, the serum leptin
concentration was the most significant biomarker (p = 0.0003).
In addition, we clearly showed for the first time that patients
with greater serum leptin concentrations were susceptible to HCC
recurrence (Fig. 2b); thus, increased serum leptin levels are a
significant independent risk factor for the recurrence of this
malignancy (Table 3). This finding indicates that increased serum
leptin concentration, which might link obesity with liver carcino-
genesis, is a preferable and useful biomarker for screening high-
risk groups for the recurrence of HCC. We previously reported
that a state of insulin resistance associated with obesity is an
independent risk factor for the recurrence of HCC after curative
treatment.(10) Furthermore, no significant correlations between
serum leptin levels and insulin resistance-related factors were
noted in the present study, suggesting these two conditions might
be independent from each other in HCC patients. Therefore, a
combination evaluation for both the serum leptin level and insulin
resistance would be more effective for screening high-risk groups
for HCC, and requires future confirmation.
Several studies report that leptin is a risk factor for carcino-
genesis at various organ sites, including the liver.(17–21) Leptin can
stimulate cellular proliferation in various types of cancer cells
such as HCC cells.(19–21,25) In addition, when focusing on the liver,
Fig. 1. Correlation between the serum levels of leptin and (a) BMI, (b) total body fat, (c) amount of visceral fat, and (d) amount of subcutaneous
fat in patients with HCC (n = 85). For BMI analysis, we excluded 7 patients with CT detected ascites.doi: 10.3164/jcbn.10 149
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leptin is a potent profibrogenic cytokine and thus plays a key role
in the progression of cirrhosis,(26) which is a precancerous
condition of HCC. Indeed, increased serum leptin concentration
has been documented in cirrhotic patients.(27,28) Moreover, increased
leptin expression is associated with increased intratumor micro-
vascular density. Consequently, it is hypothesized that leptin plays
a stimulatory role in the development of HCC via neovasculariza-
tion.(29) In addition to using leptin as a biomarker for the risk of
HCC recurrence, the present findings suggest that targeting leptin
might be an effective strategy for the prevention and treatment of
Fig. 2. Kaplan Meier curves for recurrence free survival in (a) total patients and in (b) subgroups divided on the basis of the serum leptin concen 
tration (≤5 or >5 ng/mL).
Table 2. Univariate analyses of possible risk factors for recurrence free survival of HCC using the Cox proportional hazards model
*HR represents the values with a unit increase in continuous variables. AFP, α fetoprotein; BMI, body mass index; CI, confidence interval; HbA1c,
hemoglobin A1c; HCC, hepatocellular carcinoma; HCV Ab, hepatitis C virus antibody; HOMA IR, homeostasis model assessment of insulin resistance;
HR, hazard ratio; PIVKA II, protein induced by vitamin K absence or antagonists II; RFA, radiofrequency ablation.
Variable
95% CI
HR* lower upper p value
Sex (male vs female) 0.9 0.28 3.09 0.8726
Age (years) 0.96 0.89 1.03 0.277
BMI (kg/m2) 1.3 1.08 1.56 0.0062
Total body fat (cm2) 1 1 1.01 0.0404
Amount of visceral fat (cm2) 1 0.99 1.01 0.0909
Amount of subcutaneous fat (cm2) 1 0.99 1.01 0.0601
The presence of HCV Ab (yes vs no) 0.42 0.12 1.98 0.2501
Child Pugh classification (B + C vs A) 1.33 0.35 4.3 0.6482
ALB (g/dL) 0.26 0.08 0.81 0.021
PLT (×104/μL) 0.87 0.75 1.01 0.0714
HOMA IR 1.03 0.94 1.1 0.4
HbA1c (%) 0.87 0.37 1.6 0.7108
AFP (ng/mL) 0.99 0.99 0.99 0.0365
PIVKA II (mAU/mL) 0.99 0.99 1 0.7448
Initial treatment for HCC (RFA vs resection) 1.61 0.42 10.5 0.5128
Stage (II vs I) 1.08 0.32 3.78 0.89
Leptin (ng/mL) 1.29 1.12 1.5 0.0003 J. Clin. Biochem. Nutr. | November 2011 | vol. 49 | no. 3 | 157
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HCC. Ribatti et al. state that anti-leptin antibodies reduce the
angiogenic response in HCC biopsy specimens.(29) Decreases in
serum leptin are also associated with the prevention of obesity-
related liver tumorigenesis in obese and diabetic mice models.(14)
In conclusion, we report that patients with high serum leptin
concentrations are susceptible to HCC recurrence in stage I/II
cases curatively treated by surgical resection or RFA. Increased
serum leptin concentration may be a useful biomarker for pre-
dicting the recurrence of HCC in high-risk patients.
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Table 3. Multivariate analyses of possible risk factors for recurrence free survival of HCC using the Cox proportional hazards model
*HR represents the values with a unit increase in continuous variables. AFP, α fetoprotein; BMI, body mass index; CI, confidence
interval; HR, hazard ratio.
Variable
95% CI
HR* lower upper p value
BMI (kg/m2) 1.2 0.83 1.81 0.3278
Total body fat (cm2) 1 0.99 1.01 0.8003
ALB (g/dL) 0.54 0.12 2.28 0.4018
AFP (ng/mL) 0.99 0.99 1 0.1416
Leptin (ng/mL) 1.25 1.07 1.49 0.0035
Table 4. Baseline demographic and clinical characteristics of patients classified on the basis of the serum leptin concentration
Values are median [range]. AFP, α fetoprotein; C, hepatitis C virus; FPG, fasting plasma glucose; FIRI, fasting immunoreactive insulin; HbA1c,
hemoglobin A1c; HCC, hepatocellular carcinoma; HOMA IR, homeostasis model assessment of insulin resistance; PIVKA II, protein induced by vitamin
K absence or antagonists II; RFA, radiofrequency ablation.
Variable Leptin ≤ 5 ng/mL (n = 18) Leptin > 5 ng/mL (n =1 5 ) p value
Sex (male/female) 13/5 6/9 0.0604
Age (years) 72.5 [59–87] 70 [50–85] 0.2565
BMI (kg/m2) 21.5 [17.8–30.7] 24.5 [18.5–27.7] 0.1111
Total body fat (cm2) 167.5 [73.9–490.9] 207.3 [112.2–350.8] 0.2591
Amount of visceral fat (cm2) 69.4 [19.9–294.4] 98.9 [21.9–181.6] 0.9479
Amount of subcutaneous fat (cm2) 90.2 [42.0–232.3] 134.3 [79.6–242.5] 0.0461
Etiology (C/others) 14/4 11/4 0.767
Child Pugh classification (A/B/C) 15/3/0 10/5/0 0.2657
ALB (g/dL) 3.6 [2.6–4.2] 3.3 [2.4–4.4] 0.2708
PLT (×104/μL) 12.45 [7.7–26.1] 9.5 [3.0–20.6] 0.0895
FPG (mg/dL) 97.5 [83–271] 105 [75–154] 0.7424
FIRI (μU/mL) 6.05 [2.57–65.2] 14.3 [7.3–27.4] 0.3657
HOMA IR 1.51 [0.53–24.8] 3.41 [1.45–9.40] 0.641
HbA1c (%) 5.3 [4.5–10.3] 5.2 [3.7–6.8] 0.3351
Stage (I/II) 7/11 9/6 0.2253
Initial treatment for HCC (resection/RFA) 6/12 2/13 0.1726
AFP (ng/mL) 8 [0–20500] 28 [1–2530] 0.1687
PIVKA II (mAU/mL) 22.7 [8–201000] 26 [7–29800] 0.4385doi: 10.3164/jcbn.10 149
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